ClearPoint Neuro

Harmony Biosciences (NASDAQ: HRMY) Stock Quote Follow

Last Trade: US$41.03 -0.66 -1.58
Volume: 189,627
5-Day Change: -2.12%
YTD Change: -25.54%
Market Cap: US$2.450B

Latest News From Harmony Biosciences

March 6, 2023
Harmony Biosciences To Participate In Upcoming Investor Conferences
PLYMOUTH MEETING, Pa. , March 6, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that Harmony's management team will participate in the following upcoming investor conferences: Oppenheimer 33rd Annual Healthcare Conference... Read More
February 28, 2023
Harmony Biosciences Continues Community Commitment In 2023 With Patients At The Heart And Progress At The Heart Nonprofit Funding Programs
The annual funding programs support patient-centric initiatives within rare neurological disease and sleep disorder communities Applications for Patients at the Heart and Progress at the Heart open today, Tuesday, February 28 , timed to "Rare Disease Day" PLYMOUTH MEETING, Pa. , Feb. 28, 2023 /PRNewswire/ -- Community and nonprofit organizations throughout the country that are working to support patient-centric initiatives... Read More
February 21, 2023
Harmony Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
WAKIX ® (pitolisant) Net Revenue Increased ~41% Year-over-Year to $128.3 Million for Fourth Quarter 2022; ~43% to $437.9 Million for Full Year 2022 Achieved Net Income of $181.5 Million for Full Year 2022 Average Number of Patients on WAKIX Increased to ~4,900 Continued Strong Momentum in Phase 3 Idiopathic Hypersomnia (“IH”) INTUNE Study Conference Call and Webcast to be Held Today at 8:30 a.m. ET PLYMOUTH MEETING, Pa.,... Read More
February 17, 2023
Harmony Biosciences Certified As Great Place to Work® for Fifth Consecutive Year
Recognition reinforces strong company culture and employee experience PLYMOUTH MEETING, Pa. , Feb. 17, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for people with rare neurological diseases, today announced the company has earned the Great Place to Work® recognition for the fifth year in a row.... Read More
February 7, 2023
Harmony Biosciences To Report Fourth Quarter And Full Year 2022 Financial Results On February 21, 2023
PLYMOUTH MEETING, Pa. , Feb. 7, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (NASDAQ: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that it will report fourth quarter and full year 2022 financial results on Tuesday, February 21, 2023 , before the open of the U.S. financial... Read More
January 6, 2023
Harmony Biosciences Appoints Jeffrey M. Dayno, MD as Interim CEO and Expands Role of Jeff Aronin to Executive Chairman
PLYMOUTH MEETING, Pa. , Jan. 6, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (" Harmony " or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that John C. Jacobs is stepping down as President and Chief Executive Officer and a member of the Board of Directors to pursue another... Read More
December 22, 2022
Harmony Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
PLYMOUTH MEETING, Pa. , Dec. 22, 2022 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that President and CEO, John C. Jacobs will present at the upcoming 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11,... Read More

COPYRIGHT ©2023 HEALTH STOCKS HUB